Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy.

Abstract

Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs. Mice tumor model systems are widely used in preclinical oncolytic viral therapies for evaluating the treatment regimens' efficacy. However, choosing the most appropriate model for a study can be challenging. Here, we describe a simple method of establishing subcutaneous tumors in immunocompetent mice, intratumoral injection of the virus, measuring tumor burden, and studying the survival of mice for preclinical development of oncolytic myxoma virus (MYXV).